| 000 | 01764 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515122808.0 | ||
| 264 | 0 | _c20080625 | |
| 008 | 200806s 0 0 ger d | ||
| 022 | _a1439-4413 | ||
| 024 | 7 |
_a10.1055/s-2008-1081075 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStemmler, H-J | |
| 245 | 0 | 0 |
_a[Oncology 2008]. _h[electronic resource] |
| 260 |
_bDeutsche medizinische Wochenschrift (1946) _cJun 2008 |
||
| 300 |
_a1395-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzenesulfonates _xadministration & dosage |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aCetuximab |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aEpothilones _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLapatinib |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdrug therapy |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 | _aPanitumumab |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aSorafenib |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aHeinemann, V | |
| 773 | 0 |
_tDeutsche medizinische Wochenschrift (1946) _gvol. 133 _gno. 25-26 _gp. 1395-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1055/s-2008-1081075 _zAvailable from publisher's website |
| 999 |
_c18014497 _d18014497 |
||